Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer’s diseaseGlobal quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer’s disease

ABSTRACT: Alzheimer’s disease (AD) is characterized by an early, asymptomatic phase (AsymAD) in which individuals exhibit amyloid-beta (Aβ) plaque accumulation in the absence of clinically detectable cognitive decline. Here we report an unbiased multiplex quantitative proteomic and phosphoproteomic analysis using tandem mass tag (TMT) isobaric labeling of human post-mortem cortex (n=27) across pathology-free controls, AsymAD and symptomatic AD individuals. With off-line high-pH fractionation and liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) on an Orbitrap Lumos mass spectrometer, we identified 11,378 protein groups across three TMT 11-plex batches. Immobilized metal affinity chromatography (IMAC) was used to enrich for phosphopeptides from the same TMT-labeled cases and 51,736 phosphopeptides were identified. Of these, 48,992 were quantified by TMT reporter ions representing 33,652 unique phosphosites. Two reference standards in each TMT 11-plex were included to assess intra- and inter-batch variance at the protein and peptide level. This comprehensive human brain proteome and phosphoproteome dataset will serve as a valuable resource for the identification of biochemical, cellular and signaling pathways altered during AD progression.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

SUBMITTER: Duc Duong

LAB HEAD: Nicholas Seyfried

PROVIDER: PXD020296 | Pride | 2020-09-16

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	IPI_HUMAN_042015_maptmtbrmod_abeta_apoe.fasta	Fasta
	b1_01.raw	Raw
	b1_02.raw	Raw
	b1_03.raw	Raw
	b1_04.raw	Raw

Items per page:

1 - 5 of 119

Similar Datasets

Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s Disease

Project description:Patients with Alzheimer’s disease (AD) and Parkinson disease (PD) often have overlap in brain neuropathology and clinical presentation suggesting that these two diseases share common underlying mechanisms. Currently, the molecular events linking AD and PD are incompletely understood. Utilizing 10-plex Tandem Mass Tag (TMT) assays and MultiNotch MS3 mass spectrometry, we performed an unbiased quantitative proteomic analysis of post-mortem human brain tissues (n=80) from four different groups defined as healthy controls, AD, PD, and co-morbid AD/PD cases across two brain regions (frontal cortex and anterior cingulate gyrus). In total, we identified 11,840 protein groups representing 10,230 gene symbols, which map to ~65% of the protein coding genes in brain. The utility of including two reference standards in each TMT 10-plex assay to assess intra-batch and inter-batch variance is also described. Ultimately, this comprehensive human brain proteomic dataset serves as a valuable resource for various research endeavors including, but not limited to, the identification of protein signatures and neuro-centric signaling pathways that are common or distinct in AD and PD.

2018-02-07 | PXD007160 | Pride

Proteomics analysis of prefrontal cortex from Alzheimer’s Disease patients revealed novel dysregulated proteins associated to the pathology.

Project description:Alzheimer’s disease (AD) is a neurodegenerative disease and the most common cause of dementia worldwide, but the mechanisms underlying AD are far from being elucidated. Thu, the study of proteins involved in its pathogenesis would allow getting further insights into the disease and identifying new markers for early diagnosis of AD. Our aim here is to analyze protein dysregulation in AD tissues by quantitative proteomics to identify proteins associated to the disease by 10-Plex TMT (Tandem Mass Tags)-based quantitative proteomics experiments were performed using frozen tissue samples from the left prefrontal cortex of AD patients, and healthy individuals and patients with other dementias as controls. LC-MS/MS analyses were performed using a Q Exactive mass spectrometer, and a total of 3281 proteins were identified and quantified using MaxQuant. After analysis with Perseus, 31 and 250 proteins were identified as upregulated and downregulated, respectively, at two or three Braak stages with a statistically significant ≥1.5-fold expression difference in AD patients in comparison to controls. After bioinformatics analysis, 41 dysregulated proteins were selected as more prone to be associated to AD, and 10 out of them were selected to investigate their role in the pathogenesis of AD and to verify their dysregulation in the disease by qPCR, WB, immunohistochemistry (IHC), immunofluorescence (IF), immunoprecipitation (IP) and/or ELISA, using tissue and serum samples of AD patients, patients with other dementias and healthy individuals.

2024-01-24 | PXD030751 | Pride

27-plex Tandem Mass Tag Mass Spectrometry for Profiling Brain Proteome in Alzheimer's Disease

Project description:Systematically optimized the protocol for the newly developed 16-plex TMT Reported a novel 27-plex method to enhance the multiplexity for large-scale proteomic profiling, by combining two sets of distinct isobaric tags (11-plex and 16-plex TMT) based on their disparate mass shifts on modified peptides.

2021-04-09 | PXD025261 | Pride

Ultra Deep Mouse cerebrospinal fluid (CSF) profiling in Alzheimer’s disease

Project description:Alzheimer's disease (AD) is a neurodegenerative disease, the most common cause of dementia in elderly persons. Accumulation of amyloid plaques in the brain is a characteristic of AD. The requirements for a biomarker include the ability to measure a pathologic process, predict outcome, distinguish disease or measure a pharmacological response to a drug treatment or therapeutic intervention. However, there are no reliable blood based biomarkers for AD. CSF-based protein measurement can be used as a practice for biomarkers in human disease, but comprehensive profiling of Mouse CSF proteome is often masked by the twenty most abundant proteins and impacted by large dynamic range. The commonly used depletion method can alleviate the challenge but introduce additional experimental variation. Here we present a deep analysis of un-depleted CSF proteome by combining 11-plex TMT labeling, exhaustive 2D liquid chromatography fractionation, and high resolution tandem mass spectrometry. This platform is capable of identifying 1056 protein components, covering 6 orders of dynamic range, representing one of the proteome datasets. Finally, a subset of proteins, show statistically significant difference between AD and control samples, which may serve as biomarker candidates for the AD when further correlation can be drawn from the human proteome.

2021-09-09 | PXD018658 | Pride

Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer’s disease

Project description:Alzheimer's disease (AD) is a neurodegenerative disease, the most common cause of dementia in elderly persons. Accumulation of amyloid plaques in the brain is a characteristic of AD. The requirements for a biomarker include the ability to measure a pathologic process, predict outcome, distinguish disease or measure a pharmacological response to a drug treatment or therapeutic intervention. However, there are no reliable blood based biomarkers for AD. Serum-based protein measurement is a routine practice for biomarkers in human disease, but comprehensive profiling of serum proteome is often masked by the twenty most abundant proteins and impacted by large dynamic range. The commonly used depletion method can alleviate the challenge but introduce additional experimental variation. Here we present a deep analysis of un-depleted human serum proteome by combining 11-plex TMT labeling, exhaustive 2D liquid chromatography fractionation, and high resolution tandem mass spectrometry. This platform is capable of identifying 4,500 protein components, covering 6 orders of dynamic range, representing one of the deepest serum proteome datasets. Finally, a subset of proteins, show statistically significant difference between AD and control samples, which may serve as biomarker candidates.

2019-04-23 | PXD011482 | Pride

AD and FTLD model mouse, brain, Phosphoproteome

Project description:Using a high-end mass spectrometry, we screened phosphoproteins and phosphopeptides in five types of Alzheimer's disease (AD) mouse models (5xFAD, APP-tg, PS1-tg, PS2-tg and APP-KI) and four types of frontotemporal lobar degeneration (FTLD) mouse models(CHMP2B-KI, PGRN-KI, VCP-KI and TDP43-KI) at multiple time points (1, 3 and 6 months).

2021-09-07 | PXD027119 | Pride

Profiling of post-mortem brain microRNA in Alzheimer’s disease

Project description:Non-coding RNA profiling by microarray in an Affymetrix® miRNA Array, version 4.1 (Santa Clara, CA, USA), commercially available by Thermo Fisher Scientific (Waltham, MA) We aimed to profile the expression of the entire population of annotated small non-coding RNAs in the Temporal Cortex (TC) of Alzheimer diseased (AD) individuals compared to age-matched controls.

2020-10-14 | GSE157239 | GEO

Proteomic Atlas of the Human Brain in Alzheimer’s Disease

Project description:Here we provide a proteomic resource comprising nine functionally distinct sections from three individuals clinically diagnosed with Alzheimer's disease, across a spectrum of disease progression. Using state-of-the-art mass spectrometry, we identify a core brain proteome that exhibits only small variance in expression, accompanied by a group of proteins that are highly differentially expressed in individual sections and broader regions. AD affected tissue exhibited slightly elevated levels of tau protein with similar relative expression to factors associated with the AD pathology. Substantial differences were identified between previous proteomic studies of mature adult brains and our aged cohort. Our findings suggest considerable value in examining specifically the brain proteome of aged human populations, with the goal of understanding ways in which neurological changes occur past full maturity. This resource can serve as a guide, as well as a point of reference for how specific regions of the brain are affected by aging.

2020-01-09 | PXD012131 | Pride

Proteomic Atlas of the Human Brain in Alzheimer’s Disease

2019-02-13 | PXD010603 | Pride

SIK2-dependent Phosphoproteome and Interactome upon Salmonella infection

Project description:HeLa cells transfected with non-targeting control- and anti-SIK2 siRNA were left uninfected or infected with Salmonella and lysed 30 min pi. Following tryptic-digest peptides were labeled using TMT-pro 16-plex and phosphopeptides enriched. The endogenously tagged SIK2-HA IP workflow. Hela wild type or endogenous SIK2-HA-tagged HeLa cells were left uninfected or infected with Salmonella and lysed 1 h post-infection, followed by HA-IP, Tryptic digest, TMT-labeling and LC-MS/MS analysis.

2021-05-06 | PXD021859 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data